Cell No. : Cell Name
RCB0763 : GI-1
update : 2021/02/26
|
| Comment | Human glioma separated from gliosarcoma. |
| Comment from the depositor | |
| Terms and conditions | There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC. |
| Remarks | |
| Order Form |
Order Form(C-0005.pdf)
MTA(C-0007.pdf)
MTA(C-0007p.pdf)
|
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
|
|
Basic information
|
Depositor |
Nakatu, Syouji
|
| Originator |
Iwasaki, Kouji
|
| Year of deposit |
1992
|
| Animal |
_human
< Mammals
|
| Genus |
Homo
|
| Species |
sapiens
|
| Race |
Japanese
|
| Gender |
Male
|
| Age at sampling |
61 years
|
| Tissue |
brain
|
| Disease name |
gliosarcoma
|
| Metastastatic ability |
No
|
| Classification |
cancer
|
| Memo_1 |
Mycoplasma was eliminated with MC-210 by the depositor.
|
|
Lifespan |
infinite
|
| Morphology |
fibroblast-like
|
|
| |
deposit info |
lot info |
|
Medium |
Medium List |
|
Culture type |
|
Adherent cells
|
| Medium and additives |
|
DMEM (low glucose) + 10% FBS
|
| Antibiotics |
|
Free
|
|
Passage method |
|
0.25% trypsin
|
Culture information
|
Passage ratio |
|
1 : 8 split
|
| SC frequency |
|
Subculture : 2 times/week
|
| Temperature |
|
37
℃
|
| CO2 concentration |
|
5
%
|
| Freeze medium |
|
Medium + 10% DMSO
|
| Freezing method |
|
Slow freezing
|
| Mycoplasma |
|
(-)
|
| STR(human) |
|
OK
|
| Virus (HIV) |
|
(-)
|
| Isozyme |
|
LD, NP
|
| Chromosome mode |
|
81-194(50) : /93(4),94(4),95(3),96(4),97(4),98(6)/
|
| Images |
deposit info | lot info |
|
|
|
| Reference information |
Reference |
4
|
| User's Publication |
8
|
| Reference |
|
1587
Iwasaki K, Kikuchi H, Miyatake S, Kondo S, Oda Y
Establishment of a new cell line derived from a human gliosarcoma.
Neurosurgery
1992
30:228-35
PubMed ID: 1545891
|
|
4812
Miyatake S, Kondou S, Aoki T, Iwasaki K, Ohyama K, Ootsuka S, Oda Y, Kikuchi H.
Immunomodulatory effects of interferons on target human gliosarcoma cells in the tumor-specific CTL- and LAK-mediated cytolysis]
No Shinkei Geka
1991
19(11):1053-9
PubMed ID: 1762655
|
|
4811
Miyatake S, Kikuchi H, Oda Y, Nishioka T, Takahashi J, Kondoh S, Matsumoto M, Yamasaki T, Iwasaki K, Aoki T, et al.
Decreased susceptibility of lined human gliosarcoma cells to lymphokine-activated killer cell cytolysis by gamma-interferon treatment.
Cancer Res
1990
50(3):596-600
PubMed ID: 2137025
|
|
4810
Miyatake S, Kikuchi H, Iwasaki K, Yamashita J, Li ZY, Namba Y, Hanaoka M.
Specific cytotoxic activity of T lymphocyte clones derived from a patient with gliosarcoma.
J Neurosurg
1988
69(5):751-9
PubMed ID: 3263476
|
| User's Publication |
|
11920
Takumi Chinen , Shohei Yamamoto, Yutaka Takeda , Koki Watanabe, Kanako Kuroki , Kaho Hashimoto , Daisuke Takao , Daiju Kitagawa
NuMA assemblies organize microtubule asters to establish spindle bipolarity in acentrosomal human cells
EMBO J
2020
PubMed ID: 31782546
|
|
11511
Behan FM, Iorio F, Picco G, Gonçalves E, Beaver CM, Migliardi G, Santos R, Rao Y, Sassi F, Pinnelli M, Ansari R, Harper S, Jackson DA, McRae R, Pooley R, Wilkinson P, van der Meer D, Dow D, Buser-Doepner C, Bertotti A, Trusolino L, Stronach EA, Saez-Rodriguez J, Yusa K, Garnett MJ.
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Nature
2019
PubMed ID: 30971826
|
|
12337
Agarwal S, Mohamed MS, Mizuki T, Maekawa T, Sakthi Kumar D.
Chlorotoxin modified morusin-PLGA nanoparticles for targeted glioblastoma therapy
J Mater Chem B
2019
7(39):5896-5919
PubMed ID: 31423502
|
|
9629
Sakai S, Maruyama H, Kimura T, Tajiri K, Honda J, Homma S, Aonuma K, Miyauchi T.
Antagonists to endothelin receptor type B promote apoptosis in human pulmonary arterial smooth muscle cells.
Life Sci.
2016
159:116-120
PubMed ID: 27021787
|
|
2958
Awata T, Kurihara S, Takata N, Neda T, Iizuka H, Ohkubo T, Osaki M, Watanabe M, Nakashima Y, Inukai K, Inoue I, Kawasaki I, Mori K, Yoneya S, Katayama S
Functional VEGF C-634G polymorphism is associated with development of diabetic macular edema and correlated with macular retinal thickness in type 2 diabetes.
Biochem Biophys Res Commun
2005
333:679-85
PubMed ID: 15963467
|
|
2959
Lambrechts, Diether, Storkebaum, Erik, Morimoto, Masafumi, Del-Favero, Jurgen, Desmet, Frederik, Marklund, Stefan L, Wyns, Sabine, Thijs, Vincent, Andersson, Jorgen, van Marion, Ingrid, Al-Chalabi, Ammar, Bornes, Stephanie, Musson, Rhiannon, Hansen, Valerie, Beckman, Lars, Adolfsson, Rolf, Pall, Hardev Singh, Prats, Herve, Vermeire, Severine, Rutgeerts, Paul, Katayama, Shigehiro, Awata, Takuya, Leigh, Nigel, Lang-Lazdunski, Loic, Dewerchin, Mieke, Shaw, Christopher, Moons, Lieve, Vlietinck, Robert, Morrison, Karen E, Robberecht, Wim, Van Broeckhoven, Christine, Collen, Desire, Andersen, Peter M, Carmeliet, Peter
VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death.
Nat Genet
2003
34:383-94
PubMed ID: 12847526
|
|
2550
Tamura, H O, Taniguchi K, Hayashi E, Hiyoshi Y, Nagai F
Expression profiling of sulfotransferases in human cell lines derived from extra-hepatic tissues.
Biol Pharm Bull
2001
24:1258-62
PubMed ID: 11725959
|
|
4988
Kuramoto T.
Detection of MAGE-1 tumor antigen in brain tumor.
Kurume Med J
1997
44(1):43-51
PubMed ID: 9154761
|
Back
Top
CELL BANK Website